Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
FULC Fulcrum Therapeutics	$6.90 +8.7%	$4.16	$2.32 ▼ $10.13	$372.46M	2.29	970,384 shs	997,784 shs
KMDA Kamada	$6.89 -0.9%	$6.58	$4.74 ▼ $9.16	$396.04M	0.94	90,830 shs	52,890 shs
OCUL Ocular Therapeutix	$7.89 +13.7%	$7.35	$4.79 ▼ $11.78	$1.26B	1.51	1.41 million shs	3.15 million shs
RPHM Reneo Pharmaceuticals	$1.82	$1.64	$0.98 ▼ $9.21	$60.84M	0.21	250,384 shs	437,523 shs

7 Stocks to Buy And Hold Forever

Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
FULC Fulcrum Therapeutics	-1.40%	-2.46%	+79.89%	+91.27%	-11.93%
KMDA Kamada	+4.83%	+1.16%	+3.89%	-2.11%	+31.13%
OCUL Ocular Therapeutix	-4.93%	-8.68%	-9.99%	0.00%	+19.66%
RPHM Reneo Pharmaceuticals	0.00%	0.00%	0.00%	0.00%	+9.64%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
FULC Fulcrum Therapeutics	0.5161 of 5 stars	1.2	1.0	0.0	0.0	2.7	2.5	0.0
KMDA Kamada	4.4164 of 5 stars	3.4	5.0	0.0	0.0	3.4	1.7	3.8
OCUL Ocular Therapeutix	3.7542 of 5 stars	3.4	1.0	0.0	4.1	3.5	2.5	0.0
RPHM Reneo Pharmaceuticals	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
FULC Fulcrum Therapeutics	2.43	Hold	$5.83	-15.46% Downside
KMDA Kamada	2.75	Moderate Buy	$14.67	112.87% Upside
OCUL Ocular Therapeutix	2.88	Moderate Buy	$16.25	105.96% Upside
RPHM Reneo Pharmaceuticals	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Latest FULC, OCUL, KMDA, and RPHM Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
5/23/2025	FULC Fulcrum Therapeutics	Leerink Partnrs Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Hold ➝ Strong-Buy
5/23/2025	FULC Fulcrum Therapeutics	Leerink Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Market Perform ➝ Outperform	$4.00 ➝ $12.00
5/15/2025	FULC Fulcrum Therapeutics	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Neutral ➝ Overweight	$10.00
5/15/2025	KMDA Kamada	Benchmark Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$15.00 ➝ $15.00
5/8/2025	KMDA Kamada	Sidoti Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Hold
5/6/2025	OCUL Ocular Therapeutix	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$15.00 ➝ $14.00
4/8/2025	OCUL Ocular Therapeutix	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform
4/8/2025	OCUL Ocular Therapeutix	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$15.00 ➝ $15.00
3/21/2025	KMDA Kamada	Benchmark Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$15.00
3/18/2025	OCUL Ocular Therapeutix	Royal Bank of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$17.00
3/11/2025	OCUL Ocular Therapeutix	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$15.00

(Data available from 5/28/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
FULC Fulcrum Therapeutics	$80M	4.66	N/A	N/A	$3.80 per share	1.82
KMDA Kamada	$167.24M	2.37	$0.38 per share	17.90	$4.25 per share	1.62
OCUL Ocular Therapeutix	$59.65M	21.07	N/A	N/A	$0.79 per share	9.99
RPHM Reneo Pharmaceuticals	N/A	N/A	N/A	N/A	$2.66 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
FULC Fulcrum Therapeutics	-$97.33M	-$0.07	N/A	N/A	N/A	N/A	-7.31%	-6.74%	7/30/2025 (Estimated)
KMDA Kamada	$8.28M	$0.29	24.61	21.53	0.97	9.92%	6.30%	4.49%	8/13/2025 (Estimated)
OCUL Ocular Therapeutix	-$80.74M	-$1.15	N/A	N/A	N/A	-283.74%	-45.18%	-30.87%	8/6/2025 (Estimated)
RPHM Reneo Pharmaceuticals	-$77.39M	-$2.17	N/A	N/A	N/A	N/A	-62.52%	-56.36%	N/A

Latest FULC, OCUL, KMDA, and RPHM Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/14/2025	Q1 2025	KMDA Kamada	$0.07	$0.07	N/A	$0.07	$154.06 million	$44.02 million
5/1/2025	Q1 2025	FULC Fulcrum Therapeutics	-$0.29	-$0.28	+$0.01	-$0.28	N/A	N/A
3/3/2025	Q4 2024	OCUL Ocular Therapeutix	-$0.24	-$0.29	-$0.05	-$0.29	$16.89 million	$17.08 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
FULC Fulcrum Therapeutics	N/A	N/A	N/A	N/A	N/A
KMDA Kamada	N/A	N/A	N/A	N/A	N/A
OCUL Ocular Therapeutix	N/A	N/A	N/A	N/A	N/A
RPHM Reneo Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Latest FULC, OCUL, KMDA, and RPHM Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
3/5/2025	KMDA Kamada	--	$0.20		3/17/2025	3/17/2025	4/7/2025

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
FULC Fulcrum Therapeutics	N/A	18.44	18.44
KMDA Kamada	N/A	4.84	2.73
OCUL Ocular Therapeutix	0.19	13.01	12.94
RPHM Reneo Pharmaceuticals	N/A	57.86	57.86

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
FULC Fulcrum Therapeutics	89.83%
KMDA Kamada	20.38%
OCUL Ocular Therapeutix	59.21%
RPHM Reneo Pharmaceuticals	90.98%

Insider Ownership

Company	Insider Ownership
FULC Fulcrum Therapeutics	7.00%
KMDA Kamada	36.10%
OCUL Ocular Therapeutix	2.30%
RPHM Reneo Pharmaceuticals	17.90%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
FULC Fulcrum Therapeutics	100	53.98 million	51.73 million	Optionable
KMDA Kamada	360	57.48 million	36.73 million	Optionable
OCUL Ocular Therapeutix	230	159.30 million	151.71 million	Optionable
RPHM Reneo Pharmaceuticals	30	33.43 million	27.44 million	Optionable

FULC, OCUL, KMDA, and RPHM Headlines

Recent News About These Companies

Onkure Therapeutics Inc (OKUR)

December 4, 2024 | investing.com

Cormorant Asset Management's Strategic Acquisition of Reneo Pharmaceuticals Shares

October 11, 2024 | finance.yahoo.com

Deep Track Capital's Strategic Investment in Reneo Pharmaceuticals

October 11, 2024 | finance.yahoo.com

Carlyle Group Inc. Reduces Stake in Reneo Pharmaceuticals Inc.

October 10, 2024 | finance.yahoo.com

Reneo Pharmaceuticals: Navigating Financial Challenges and Corporate Changes

October 9, 2024 | finance.yahoo.com

OnKure Announces Closing of Merger with Reneo Pharmaceuticals and Concurrent Private Placement of $65 Million

October 4, 2024 | globenewswire.com

Baosheng Media Gr (NASDAQ:BAOS) Stock Quotes, Forecast and News Summary

October 3, 2024 | benzinga.com

Reneo Pharmaceuticals Announces Stockholder Approval of Merger with OnKure

October 2, 2024 | globenewswire.com

Braden Michael Leonard Acquires 29,600 Shares of Reneo Pharmaceuticals, Inc. (NASDAQ:RPHM) Stock

September 27, 2024 | insidertrades.com

Braden Michael Leonard Purchases 55,300 Shares of Reneo Pharmaceuticals, Inc. (NASDAQ:RPHM) Stock

September 20, 2024 | insidertrades.com

Reneo Pharmaceuticals Inc (RPHM) Stock: More Resilient Than It Appears

September 15, 2024 | bovnews.com

Color Star Tech (NASDAQ:ADD) Stock Quotes, Forecast and News Summary

September 12, 2024 | benzinga.com

Reneo Pharmaceuticals insider buys shares worth over $380k

August 16, 2024 | investing.com

Reneo Pharmaceuticals, Inc. (NASDAQ:RPHM) Major Shareholder Braden Michael Leonard Acquires 171,339 Shares

August 15, 2024 | insidertrades.com

RPHM Stock Earnings: Reneo Pharmaceuticals Misses EPS for Q2 2024

August 13, 2024 | investorplace.com

Reneo Pharmaceuticals Reports Second Quarter 2024 Financial Results

August 13, 2024 | globenewswire.com

STOCKHOLDER INVESTIGATION: The M&A Class Action Firm Investigates Merger of Reneo Pharmaceuticals, Inc. - RPHM

June 26, 2024 | globenewswire.com

STOCKHOLDER INVESTIGATION: The M&A Class Action Firm Investigates Merger of Reneo Pharmaceuticals, Inc. - RPHM

June 24, 2024 | prnewswire.com

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates AAN, RPHM on Behalf of Shareholders

June 21, 2024 | globenewswire.com

STOCKHOLDER INVESTIGATION: The M&A Class Action Firm Investigates Merger of Reneo Pharmaceuticals, Inc. - RPHM

June 21, 2024 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

FULC, OCUL, KMDA, and RPHM Company Descriptions

Fulcrum Therapeutics NASDAQ:FULC

$6.90 +0.55 (+8.66%)

Closing price 04:00 PM Eastern

Extended Trading

$7.42 +0.52 (+7.54%)

As of 07:37 PM Eastern

Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy is under phase III clinical trial; and pociredir, a fetal hemoglobin inducer for the treatment of sickle cell disease and beta-thalassemia is under phase I clinical trial. The company is also discovering drug targets for the treatments of rare neuromuscular, muscular, central nervous system, and hematologic disorders, as well as cardiomyopathies and pulmonary diseases. Fulcrum Therapeutics, Inc. has collaboration and license agreement with Acceleron Pharma Inc. to identify biological targets to modulate specific pathways associated with a targeted indication within the pulmonary disease space; and MyoKardia, Inc. to discover and develop therapies for the treatment of genetic cardiomyopathies. Fulcrum Therapeutics, Inc. was Incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

Kamada NASDAQ:KMDA

$6.89 -0.06 (-0.86%)

Closing price 04:00 PM Eastern

Extended Trading

$6.87 -0.02 (-0.29%)

As of 04:04 PM Eastern

Kamada Ltd. manufactures and sells plasma-derived protein therapeutics. Its commercial products include KAMRAB/KEDRAB for treating prophylaxis of rabies; CYTOGAM for Prophylaxis of Cytomegalovirus disease in kidney, lung, liver, pancreas, heart, and heart/lung transplants; VARIZIG for post exposure prophylaxis of varicella; WINRHO SDF for immune thrombocytopenic purpura and suppression of rhesus isoimmunization; HEPAGAM B for prevention of hepatitis B recurrence liver transplants and post-exposure prophylaxis; GLASSIA for intravenous AATD; KAMRHO (D) IM for prophylaxis of hemolytic disease of newborns; KAMRHO (D) IV for immune thermobocytopunic purpura; and Echis coloratus and Vipera palaestinae Antiserum for the treatment of snake bite. The company also distributes imported drug products in Israel, including BRAMITOB to manage chronic pulmonary infection; FOSTER to treat asthma; TRIMBOW for chronic obstructive pulmonary disease; PROVOCHOLINE for the diagnosis of bronchial airway hyperactivity; AEROBIKA, an OPEP device; RUPAFIN and RUPAFIN ORAL SOLUTION for allergic rhinitis and Urticaria; SINTREDIUS for rheumatoid arthritis, systemic lupus erythematosus, and mild-moderate juvenile dermatomyositis; IVIG for immunodeficiency-related conditions; VARITECT for chicken pox and zoster herpes; ZUTECTRA and HEPATECT CP for hepatitis B; MEGALOTECT CP for CMV virus; RUCONEST for angioedema attack; HEPARIN SODIUM INJECTION for thrombo-embolic disorders and prophylaxis of deep vein thrombosis and thromboembolic events; ALBUMIN and ALBUMIN for blood plasma; Factor VIII for hemophilia type A; and Factor IX for hemophilia type B. In addition, it distributes COAGADEX for hereditary factor X deficiency; IXIARO for Japanese encephalitis; VIVOTIF for Salmonella Typhi; PROCYSBI for nephropathic cystinosis; LAMZEDE for alpha-mannosidosis; ELIGARD for prostate cancer; and BEVACIZUMAB KAMADA for various cancers. The company was incorporated in 1990 and is headquartered in Rehovot, Israel.

Ocular Therapeutix NASDAQ:OCUL

$7.89 +0.95 (+13.69%)

Closing price 04:00 PM Eastern

Extended Trading

$7.99 +0.10 (+1.32%)

As of 07:56 PM Eastern

Ocular Therapeutix, Inc., a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis. It is developing AXPAXLI, an axitinib intravitreal implant that is in phase 3 trials for the treatment of wet age-related macular degeneration and other retinal diseases; PAXTRAVA, a travoprost intracameral implant, which is in phase 2 clinical trials for the treatment of open-angle glaucoma or ocular hypertension; OTX-CSI, a cyclosporine intracanalicular insert that has completed phase 2 clinical trials for the treatment of dry eye disease; and OTX-DED, a dexamethasone intracanalicular insert, which is in phase 2 clinical trials for the short-term treatment of the signs and symptoms of dry eye disease. In addition, the company offers modulator for intermediate and late dry age-related macular degeneration; and gene delivery for inherited retinal degenerations and protein biofactory indications. The company has a strategic collaboration with Regeneron Pharmaceuticals, Inc. (Regeneron) for the development and commercialization of products using the company's sustained-release hydrogel in combination with Regeneron's large molecule VEGF-targeting compounds for the treatment of retinal diseases; and AffaMed Therapeutics Limited for the development and commercialization of DEXTENZA and OTX-TIC. Ocular Therapeutix, Inc. was incorporated in 2006 and is headquartered in Bedford, Massachusetts.

Reneo Pharmaceuticals NASDAQ:RPHM

Reneo Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the development and commercialization of therapies for patients with rare genetic mitochondrial diseases. The company's lead product candidate is REN001, a potent and selective agonist of the peroxisome proliferator-activated receptor delta that is in clinical development for genetic mitochondrial diseases comprising primary mitochondrial myopathies and long-chain fatty acid oxidation disorders. Reneo Pharmaceuticals, Inc. was incorporated in 2014 and is headquartered in Irvine, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time